The PennZone

  • Home
  • Non-profit
  • Business
  • Education
  • Technology
  • Construction
  • Entertainment
  • Health
  • Software

Olympus Acquires Veran Medical Technologies, Inc.
The PennZone/10102444

Trending...
  • Global.ai Appoints Freedomtech Solutions as Specialist Partner for Agentic AI
  • Autism Podcast Helps Parents Understand Why Behavior Is Communication, Not Defiance
  • Love Must Be the Guide: Live Good Shares a Message of Humanity, Compassion and Hope
CENTER VALLEY, Pa. and TOKYO, Dec. 30, 2020 /PRNewswire/ -- Olympus Corporation today announced that it has finalized the acquisition of Veran Medical Technologies, Inc. (VMT), a leading provider of advanced medical devices specializing in interventional pulmonology, following the definitive agreement the two companies signed December 4, 2020. With this acquisition by Olympus subsidiary Olympus Corporation of the Americas (OCA), Olympus gains VMT's global sales network, marketing, manufacturing, R&D, and other functions to expand the Olympus respiratory product portfolio.

Lung cancer is the leading cause of cancer-related deaths globally.1 With increased awareness and more lung cancer screenings using low-dose computed tomography (CT), the need for definitive diagnosis of lesions in the peripheral regions of the lungs by tissue biopsy is expected to increase. VMT's SPiN Thoracic Navigation System® and related devices are specifically designed to help physicians navigate to, localize, and sample peripheral pulmonary lesions. Together with the existing Olympus respiratory portfolio that includes radial endobronchial ultrasound (EBUS) and thin bronchoscopes, VMT's navigational system and related devices provide a powerful combination of imaging, access and precision for pulmonologists seeking to diagnose and determine the stage of a patient's lung cancer.

More on The PennZone
  • America's Workforce Solution, LLC Assessed "Awardable" for Department of War work in the CDAO's Tradewinds Solutions Marketplace
  • Speaker and Certified Coach Syrena N. Williams Debuts Powerful New Book on Healing, Identity, and Wholeness
  • Lord of the Rings, Doctor Who' Q&As, Local Sessions Highlight FAN EXPO Philadelphia Programming
  • Kryptokasinot.io Raises Concerns Over Proposed Cryptocurrency Restrictions in Finland's Gambling Reform
  • New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan

"We are very excited about the synergies this acquisition creates. With the deal now closed, as one company we are able to combine Olympus' expertise and clinical history in minimally invasive technology with the innovation in navigation systems of Veran Medical Technology to improve workflow and patient care in lung cancer," said Lynn Ray, Vice President and General Manager of the Global Respiratory Business Unit for Olympus Corporation. "Olympus is committed to providing the medical community with the best tools possible to use in their fight against cancer. With the advent of EBUS-guided transbronchial needle aspiration (EBUS-TBNA) in 2004, Olympus brought patients the benefit of more accurate diagnosis and staging, to improve patient outcomes and care. We are thrilled to be at the forefront of development in this rapidly evolving area of respiratory care."

The acquisition will provide immediate incremental revenue and an experienced sales team within the U.S. market. VMT's advanced and proven navigation technology, together with Olympus' respiratory portfolio, strengthens and enhances Olympus' global position as a medical technology innovator.

As part of its current Corporate Strategy, Olympus vowed to "focus and scale" its Therapeutic solutions Division (TSD). To accelerate the process and provide greater agility, Olympus made OCA the TSD headquarters, recognizing the significant growth opportunities in North America. Olympus also identified three core medical fields to prioritize and has since focused on gastroenterological endotherapy devices, urological devices, and respiratory devices. The VMT acquisition is centered on respiratory devices and will position Olympus as a leader in this field.

More on The PennZone
  • The Calida Group Announces Sale of Ely at Fort Apache for $57.5 Million
  • Tina Hasselbusch, co-founder and CEO of Turnstone Creative, Receives Circle of Excellence from Lehigh Valley Business
  • Summer Festivals in Gunma Prefecture: Song, Dance, and Vibrant Color – Get There Via Tobu Railway!
  • Jetperch Introduces Joulescope JS320 Precision Energy Analyzer for Low-Power Embedded System Development
  • AI-Powered Trading Bots Are Transforming Forex, Gold, and Digital Markets as DefiHash Expands Intelligent Quantitative Infrastructure

For additional information, please refer to our corporate disclosure, "Notice regarding acquisition of Veran Medical Technologies, Inc. in the United States."

(available at: https://www.olympus-global.com/news/ir/2020/)

1 WHO data:  https://www.who.int/news-room/fact-sheets/detail/cancer

About Olympus' Therapeutic Solutions Division
In its Therapeutic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Starting with its early contributions to the development of the polypectomy snare, Olympus' Therapeutic Solutions portfolio has grown to include an array of surgical energy devices and a wide range of instruments to help prevent, detect, and treat disease. For more information, visit www.olympus-global.com.

SOURCE Olympus

Related Links

http://www.olympus.com/
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • VIV Welcomes Residents to St. Petersburg's EDGE District
  • Evocative Joins the Independent Data Centre Network (IDCN) as Primary USA Operator
  • Philadelphia Scientist Roohid Parast Advances IBD Research at Johnson & Johnson
  • Medical Experts Highlight the Importance of Second Opinions in Death Investigations
  • Joseph Nybyk aka Neibich of Gilbert, Arizona
  • Omnitronics Unveils 100% Software omniGateDMR and omniGateP25 RoIP Gateways
  • KRE PRIME Launches Adaptive Convertible Jumpsuit
  • USA Med Bed Helping Home Care Patients with Refurbished Hill Rom Hospital Beds
  • Sobreseimiento de Nicolás dos Santos y Jorge Méndez expone demandas millonarias a Paraguay y boicot a la Hidrovía
  • CAPHRA warns Southeast Asia not to repeat Australia's nicotine policy failure
  • Milo3D.ai Launches Free AI 3D Model Generator That Turns Text and Images Into Game-Ready 3D Assets in Seconds
  • UK Financial Ltd Executes 100% Success Rate on All ERC-3643 Transfers to Coin Holders of MayaCat Regulated Security Token and Maya Preferred PRA
  • Blank Space: The Unofficial Taylor Swift Tribute Brings Eras Tour Magic To Cities Across America
  • Love Must Be the Guide: Live Good Shares a Message of Humanity, Compassion and Hope
  • D.R. Crotzer Announces A New Science Fiction Book Series Exploring Life Energy, Dreams, and the Mystery of Existence
  • Vinnie Rocco Opens AgentiX Minds To Help Business Owners & Execs Learn AI Agents
  • Color Card Administrator Highlights Growing Enterprise Demand for Operational Infrastructure in Business Card Identity Governance
  • American Properties Celebrates Grand Opening and Ribbon Cutting Ceremony at Heritage at South
  • MoMojo Records signs Arlen Roth; "Blues Grass" slated for August 7, 2026 release
  • Crosswalk Ministries USA Announces 2026 Child and Family Well-Being Conference in Stockbridge, Georgia

Popular on PennZone

  • Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
  • People & Stories/Gente y Cuentos Welcomes Two New Trustees as Organization Enters 54th Year and Expands Community Reach
  • Assymetrix Launches the Deepest Independent Prediction Market Data API
  • Strategic Talent Associates Launches THE ALIGNED RESET™
  • AWARENESS TO WELLNESS: Imhotep Institute Charter High School
  • Resident Inspect Joins Property Meld Nexus Network with API Integration
  • New plusOne Research Finds the Orgasm Gap Is a 30-Point Chasm — and Confirms It Isn't Biology
  • New Homesites Released at Heritage at Manalapan Featuring Scenic Golf Course Views
  • RAS AP Consulting Advances to RFP Stage in Heidelberg Materials' SAP Vendor & Customer Master Data Modernization Initiative
  • Expert E-Bike Safety Advocate Issues Urgent Warning Following Recent Southern California Fatalities

Similar on PennZone

  • Milton Collier, CEO & President of Freight Broker 911, Eliminates the #1 Barrier to Entry in Logistics: Announces 100% Free Freight Broker Training
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
  • KRE PRIME Launches Adaptive Convertible Jumpsuit
  • Sobreseimiento de Nicolás dos Santos y Jorge Méndez expone demandas millonarias a Paraguay y boicot a la Hidrovía
  • UK Financial Ltd Executes 100% Success Rate on All ERC-3643 Transfers to Coin Holders of MayaCat Regulated Security Token and Maya Preferred PRA
  • Global.ai Appoints Freedomtech Solutions as Specialist Partner for Agentic AI
  • Triple-Digit Growth, OTCQX Market Upgrade and a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation: Stock Symbol: CDIX
  • XRPPower Continues Strengthening Its Global AI-Powered Blockchain Ecosystem
  • Advanced AI Capabilities Reflected by Upcoming Company Name and Stock Symbol Change for Evolving Pre-Owned Boat Dealer: Off The Hook YS: N Y S E: OTH
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us